{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:58:43Z","timestamp":1788026323836,"version":"build-2784847793"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Dermavant Sciences, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40257-025-00929-9","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T22:28:05Z","timestamp":1743028085000},"page":"449-456","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Maximal Usage Trial of Tapinarof Cream 1% Once Daily in Pediatric Patients Down to 2 Years of Age with Extensive Atopic Dermatitis"],"prefix":"10.1007","volume":"26","clinical-trial-number":[{"clinical-trial-number":"nct05186805","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-6549","authenticated-orcid":false,"given":"Amy S.","family":"Paller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9167-5729","authenticated-orcid":false,"given":"Adelaide A.","family":"Hebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8346-8298","authenticated-orcid":false,"given":"Mercedes E.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0648-310X","authenticated-orcid":false,"given":"Victoria","family":"Butners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9668-8270","authenticated-orcid":false,"given":"Glenn","family":"Tabolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0302-8722","authenticated-orcid":false,"given":"David S.","family":"Rubenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-3273","authenticated-orcid":false,"given":"Stephen C.","family":"Piscitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"929_CR1","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.jaci.2017.01.009","volume":"139","author":"LF Eichenfield","year":"2017","unstructured":"Eichenfield LF, Ahluwalia J, Waldman A, Borok J, Udkoff J, Boguniewicz M. Current guidelines for the evaluation and management of atopic dermatitis: a comparison of the Joint Task Force practice parameter and American Academy of Dermatology guidelines. J Allergy Clin Immunol. 2017;139:S49\u201357.","journal-title":"J Allergy Clin Immunol"},{"issue":"10\u201322","key":"929_CR2","volume":"120","author":"M Boguniewicz","year":"2018","unstructured":"Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(10\u201322): e2.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"929_CR3","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","volume":"137","author":"SH Smith","year":"2017","unstructured":"Smith SH, Jayawickreme C, Rickard DJ, Nicodeme E, Bui T, Simmons C, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017;137:2110\u20139.","journal-title":"J Invest Dermatol"},{"key":"929_CR4","doi-asserted-by":"crossref","unstructured":"Bissonnette R, Stein Gold L, Kircik L, Simpson E, Eichenfield LF, Browning J, et al. Skin clearance, treatment response off-therapy, and safety of Tapinarof cream 1% once daily: results from ADORING 3, a 48-week Phase 3 trial in adults and children down to 2 years of age with atopic dermatitis. Poster presentation at Fall Clinical Dermatology Conference 2024. Las Vegas, NV, USA. October 24\u201327, 2024.","DOI":"10.25251\/skin.8.supp.460"},{"key":"929_CR5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2024.05.023","volume":"91","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Eichenfield LF, Hebert AA, Simpson EL, Stein Gold L, Bissonnette R, et al. Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol. 2024;91:457\u201365.","journal-title":"J Am Acad Dermatol"},{"key":"929_CR6","unstructured":"Dermavant Sciences, Inc. VTAMA\u00ae (tapinarof) cream, 1%: US prescribing information. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215272s002lbl.pdf. Accessed Jan 2024."},{"key":"929_CR7","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaad.2022.06.1171","volume":"87","author":"B Strober","year":"2022","unstructured":"Strober B, Stein Gold L, Bissonnette R, Armstrong AW, Kircik L, Tyring SK, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial. J Am Acad Dermatol. 2022;87:800\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"929_CR8","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","volume":"385","author":"MG Lebwohl","year":"2021","unstructured":"Lebwohl MG, Stein Gold L, Strober B, Papp KA, Armstrong AW, Bagel J, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385:2219\u201329.","journal-title":"N Engl J Med"},{"key":"929_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/2168479014539157","volume":"49","author":"ED Bashaw","year":"2015","unstructured":"Bashaw ED, Tran DC, Shukla CG, Liu X. Maximal usage trial: an overview of the design of systemic bioavailability trial for topical dermatological products. Ther Innov Regul Sci. 2015;49:108\u201315.","journal-title":"Ther Innov Regul Sci."},{"key":"929_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40257-021-00641-4","volume":"23","author":"JE Jett","year":"2022","unstructured":"Jett JE, McLaughlin M, Lee MS, Parish LC, DuBois J, Raoof TJ, et al. Tapinarof cream 1% for extensive plaque psoriasis: a maximal use trial on safety, tolerability, and pharmacokinetics. Am J Clin Dermatol. 2022;23:83\u201391.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"929_CR11","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","volume":"84","author":"R Bissonnette","year":"2021","unstructured":"Bissonnette R, Stein Gold L, Rubenstein DS, Tallman AM, Armstrong A. Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. J Am Acad Dermatol. 2021;84(4):1059\u201367.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"929_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2023.12.013","volume":"154","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Boguniewicz M, Quintana FJ, Clark RA, Gross L, Hirano I, et al. Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: a clinical review. J Allergy Clin Immunol. 2024;154(1):1\u201310.","journal-title":"J Allergy Clin Immunol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00929-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00929-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00929-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T07:56:42Z","timestamp":1747468602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00929-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["929"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00929-9","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"assertion":[{"value":"4 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Supported by Dermavant Sciences, Inc. Medical writing and editorial assistance were funded by Dermavant Sciences, an Organon Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Amy S. Paller is an investigator, without personal compensation, for AbbVie, Applied Pharma Research, Biomendics, Dermavant Sciences, Inc., Eli Lilly, Incyte, Janssen, Krystal Biotech, Regeneron, Timber, and UCB Pharma; a consultant (with honoraria) for Abeona, Apogee, Arcutis, Aslan, BioCryst, Boehringer Ingelheim, Bristol Myers Squibb, Castle Creek, Dermavant Sciences, Inc., Incyte, Krystal Biotech, LEO Pharma, L\u2019Oreal, Mitsubishi Tanabe, MoonLake Immunotherapeutics, Procter & Gamble, Regeneron, Sanofi\/Genzyme, Seanergy, and UCB Pharma; and on the Data Safety Monitoring Board for AbbVie, Abeona, and Galderma. Amy S. Paller is an Editorial Board member of the American Journal of Clinical Dermatology; she was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Adelaide A. Hebert is an investigator without personal compensation for research support for AbbVie, Amgen, Arcutis, Dermavant Sciences, Inc., and Pfizer; and has received honoraria from Arcutis, Almirall, Incyte, LEO Pharma, Mayne, Novan, Pfizer, and Verrica; and is on Data Safety Monitoring Boards for GSK, Ortho Dermatologics, and Sanofi Regeneron. Mercedes E. Gonzalez has been an investigator for AbbVie, Arcutis, Amgen, Anterogen, Dermavant Sciences, Inc., Eli Lilly, Incyte, Krystal Biotech, Neilsen Biosciences, Novartis, Pfizer, Regeneron, Sanofi\/Genzyme; a consultant with honorarium for Abeona, Arcutis, Alphyn, Apogee, Chiesi, Dermavant Sciences, Inc., Eli Lilly, Galderma, Incyte, Kenvue, Krystal Biotech, LEO Pharma, Pelthos Therapeutics, and Verrica; and on the speakers bureau for AbbVie, Arcutis, Eli Lilly, Galderma, Krystal Biotech, LEO Pharma, Pfizer, Regeneron, Sanofi\/Genzyme, and Verrica. Victoria Butners, Glenn Tabolt, and David S. Rubenstein are former employees of Dermavant Sciences, Inc. Nancy Fitzgerald and Stephen C. Piscitelli are employees of Dermavant Sciences, an Organon Company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data that support the findings of the trials and studies are proprietary and are not publicly available. The data may be made available upon reasonable request and with permission from Dermavant Sciences, an Organon Company, but restrictions will apply to the availability of these data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The trial was approved by the central Institutional Review Board, Advarra (July 30, 2021), and conducted in accordance with the ethical principles of the Declaration of Helsinki, the International Conference on Harmonisation guidelines, Good Clinical Practice, and local applicable regulatory requirements.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients and\/or their parents\/legal guardians prior to the start of trial treatment.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent to publish"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Stephen C. Piscitelli wrote the first draft, and all authors contributed to the critical revision of the manuscript. All authors have read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}